Showing 4461-4470 of 5627 results for "".
- New Educational Resource On Importance of Eye Protection in Sports/Recreational Activititeshttps://modernod.com/news/new-educational-resource-on-importance-of-eye-protection-in-sports-recreational-activitites/2479046/The International Sports Vision Association (ISVA) and Zyloware Eyewear announced the launch of Protect. Prevent. Play., a new educational resource designed to help eye care professionals educate parents, coaches, teachers, athletic trainers and athletes of all ages and skill levels abou
- Large Employers are Eyeing On-Site COVID-19 Vaccines, Survey Showshttps://modernod.com/news/large-employers-are-eyeing-on-site-covid-19-vaccines-survey-shows/2479044/Many large employers are expecting to offer COVID-19 vaccines on-site for workers by the end of the year, a new survey shows, according to a Fierce Healthcare
- Eyenovia Announces Appointment of Julia Haller, MD, to its Board of Directorshttps://modernod.com/news/eyenovia-announces-appointment-of-julia-haller-md-to-its-board-of-directors/2479041/Eyenovia announced the appointment of Julia Haller, MD, to its Board of Directors. “We are delighted to welcome Dr. Haller to our Board of Directors at such an exciting time for Eyenovia,” Sean Ianchulev, MD, PhD, Chief Executive Officer and Chief Medical
- Outlook Therapeutics Reports Positive Safety Profile from NORSE THREE Study for Lytenavahttps://modernod.com/news/outlook-therapeutics-reports-positive-safety-profile-from-norse-three-study-for-lytenava/2479037/Outlook Therapeutics announced positive topline results from its NORSE THREE open-label safety study evaluating ONS-5010/Lytenava (bevacizumab-vikg) to treat retinal diseases. Topline results from the open-label safety study demonstrated that ONS-5010 showed no unexpecte
- Nanoform and Nacuity Pharmaceuticals Sign Technology Proof of Concept Agreement for Two Ophthalmic Drug Candidateshttps://modernod.com/news/nanoform-and-nacuity-pharmaceuticals-sign-technology-proof-of-concept-agreement-for-two-ophthalmic-drug-candidates/2479035/Nanoform Finland and Nacuity Pharmaceuticals announced that they have signed a Technology Proof of Concept Agreement, with compensation on standard commercial terms. This will apply Nanoform’s nanoparticle CESS technology to enhance ophthalmic drug delivery of Nacuity’s NPI-001 and N
- AffaMed Therapeutics and SIFI Announce Joint Venture to Serve Greater China Markethttps://modernod.com/news/affamed-therapeutics-and-sifi-announce-joint-venture-to-serve-greater-china-market/2479036/AffaMed Therapeutics and SIFI S.p.A. announced they have entered into an agreement to establish a joint venture to develop, manufacture and commercialize premium IOLs in the Greater China market, including Mainland China, Taiwan, Macau and Hong Kong. AffaMed will provide funding for growth
- Study: Drinking Wine May Help Protect Against Cataractshttps://modernod.com/news/study-drinking-wine-may-help-protect-against-cataracts/2479033/People who consume alcohol moderately appear less likely to develop cataracts that require surgery. Wine consumption showed the strongest protective effect, suggesting that antioxidants which are abundant in red wine may play a role in cataract prevention. However, people who d
- UMass Medical School and AEYE Health Leverage AI to Help Family Doctors Screen and Refer Patients With Eye Conditions to Specialistshttps://modernod.com/news/umass-medical-school-and-aeye-health-leverage-ai-to-help-family-doctors-screen-and-refer-patients-with-eye-conditions-to-specialists/2479031/AEYE Health and UMass Medical School, in collaboration with UMass Memorial Health Care, are developing a system which enables family doctors to screen patients for various retinal conditions and enable timely referrals to specialists. As part of this effort, AEY
- FDA Approves Rayner’s RayOne EMV IOLhttps://modernod.com/news/fda-approves-rayners-rayone-emv-iol/2479019/Rayner’s RayOne EMV fully preloaded non-diffractive IOL has received FDA approval. RayOne EMV was developed in collaboration with renowned surgeon Professor Graham Barrett, president of the Australasian Society of Cataract & Refractive Surgeons. Dr. Mariano Royo, Director
- Pfizer, BioNTech Initiate Study of COVID-19 Vaccine in Children Under 12https://modernod.com/news/pfizer-biontech-initiate-study-of-covid-19-vaccine-in-children-under-12/2479017/Pfizer and BioNTech said Thursday that they have started testing their COVID-19 vaccine BNT162b2 in children ages 6 months to 11 years old, with initial results expected in the second half of the year. The mRNA-based vaccine is currently authorized for people 16 years and older in multiple market